Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Neurobiol Aging. 2019 Dec 16;89:41–54. doi: 10.1016/j.neurobiolaging.2019.12.009

Fig. 7.

Fig. 7.

The ROCK inhibitor (H1152) reduced tau in the sarkosyl-insoluble fraction and oligomeric tau. The ROCK inhibitor (H1152) reduced total tau (Tau5) and phosphorylated tau (PHF-1) in the sarkosyl insoluble fraction (S/P) and Tris-insoluble, sarkosyl-soluble fraction (SN2). (N = 4) **p < 0.01, *p < 0.05, Bar ± SD (A). In the Tris-insoluble, sarkosyl-soluble fraction, the levels of high molecular weight smear total tau (Tau5) and phosphorylated tau (PS199/202) were decreased by the ROCK inhibitor (H1152) under nonreducing conditions. N = 3, *p < 0.05 (B). (C) Dot blot analysis of lysate demonstrated the reduction of oligomeric tau by ROCK inhibitor (H1152). −: ROCK inhibitor (−), +: 1 μM ROCK inhibitor-treated cells. N = 4, *p<0.05, Bar ± SD. (D) Immunocytochemical study also showed that ROCK inhibitor treatment decreased oligomeric tau as detected by TOC1. −: DMSO, +: 1 μM ROCK inhibitor (H1152), Scale: 75 μM, **p < 0.01, Bar ± SD. For the total tau (Tau5) and phosphorylated tau (PHF-1) in the sarkosyl insoluble fraction (S/P) and Tris-insoluble, sarkosyl-soluble fraction (SN2), high molecular weight smear total tau and phosphorylated tau, and immunocytochemical study of TOC1, the data followed a normal distribution and were analyzed with Student’s t-test, whereas dot blot data were analyzed with the Mann-Whitney U-test because the data deviated from a normal distribution. Abbreviation: ROCK, Rho-associated coiled-coil protein kinase; TOC1, Tau Oligomer Complex I antibody.